B+
Bull case
25%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-09-29 · RankAlpha Sentiment Codex
APYX
Apyx MedicalDNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$2.90
Analysis reference price unavailable
Analysis 2026-09-29 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.60
Analysis reference price unavailable
Analysis 2026-09-29 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-29
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+66.2
Score
AI commentary
Company-reported Q2 operating trends were constructive, but coverage is thin. The September 28 anchor of $2.50 is below the prior baseline's September 10 anchor of $2.89; that comparison does not isolate an earnings-day reaction. Current analyst revisions, options skew, short interest and sufficient social-sentiment observations were not supplied; zero sentiment fields denote unavailable data, not neutral measurements.
RankAlpha Sentiment Codex - 2026-09-29
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventTest of reaffirmed FY2026 guidanceHigh impact
Apyx reaffirmed FY2026 revenue guidance of $59–60 million after Q2 revenue rose 22% to $13.9 million. The remaining-year test is whether AYON-led Surgical Aesthetics growth offsets declining OEM sales. The August results release was furnished with the 8-K. [#SEC-8K-2026-08-06] SEC Exhibit 99.1
2026-12-31catalystAYON power-liposuction rolloutHigh impact
Following expanded FDA 510(k) clearance, Apyx began limited shipments of AYON's reusable power-liposuction handpiece in June. Broader surgeon uptake and repeat handpiece use remain unproven. SEC Exhibit 99.1
2027-06-30catalystAYON growth versus cash consumptionHigh impact
Q2 Surgical Aesthetics revenue grew 28%, but operating cash use increased to $3.5 million. Durable adoption must improve cash generation before management's projected cash runway through 2027 can be treated as secure. SEC Exhibit 99.1
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-29 • Updated nightlySource: Internal modelMethodology